Boston Scientific trims outlook again

Boston Scientific trims 2026 sales and earnings guidance due to slowing growth in key product lines, including Watchman…

Abbott launches a comprehensive heart valve study assessing its TriClip device's real-world safety and performance in treating tricuspid…

Boston Scientific restructuring plan will incur up to $800 M in pre‑tax charges as the company shifts production…

Prevent drug diversion with multidisciplinary auditing and procurement checks beyond diversion surveillance software effectively.

Ravulizumab trial results reveal no significant improvement in event‑free survival for HSCT‑TMA patients, highlighting challenges in this rare…

Discover the latest guidance on switching disease-modifying therapies for multiple sclerosis patients, focusing on hit-hard-and-early treatment era strategies…

Regular coffee intake is linked to lower disease risk, with up to 400 mg of caffeine daily considered…

Lung cancer treatment raises safety concerns with atezolizumab and consolidative thoracic radiotherapy combination.

Sacituzumab govitecan is a new first-line treatment option for breast cancer patients with metastatic triple-negative breast cancer.

Flu vaccination rates in the US have dropped to 43.8% for adults and children. Learn why coverage is…